阿尔茨海默病临床试验障碍 在少数群体中参与临床试验
Anson Y Lee1,2, Julia R Jahansooz1,2, Darrell Guittu1
1Memory Disorders Center & Alzheimer's Research Unit, Hawaii Pacific Neuroscience, Honolulu, Hawaii.
概括
缺乏信息阻碍了亚洲和夏威夷原住民患者参与阿尔茨海默病 (AD) 临床试验. 增加外展和教育对于改善阿尔茨海默病研究的入学率至关重要.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 健康差异 在健康上的差异
背景情况:
- 阿尔茨海默病 (AD) 不成比例地影响美国的少数群体.
- 了解AD临床试验中的参与障碍对于公平的研究至关重要.
研究的目的:
- 确定亚洲和夏威夷原住民患者参与AD临床试验的障碍.
- 探索改善这些人口群体试验招生的潜在策略.
主要方法:
- 对187名被诊断患有AD或轻度认知障碍的患者进行了一项调查 (MMSE得分≥14).
- 该调查评估了人口统计数据,参与障碍以及改善试验的建议.
- 通过49名患者的反应,获得了26%的应答率.
主要成果:
- 与白人患者相比,亚洲人和夏威夷原住民患者在阿尔茨海默病试验中的参与率较低.
- 发现的主要障碍是缺乏关于可用的AD试验的信息.
- 患者表示,增加信息和后勤支持将鼓励参与.
结论:
- 在AD临床试验中,亚洲和夏威夷原住民患者的主要障碍是信息不足.
- 运输困难和时间承诺也带来了挑战,特别是对于亚洲参与者来说.
- 建议加强外展,教育和后勤支持,以提高这些人群的参与率.
相关概念视频
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
02:16Surveys
14.8K
Often, psychologists develop surveys as a means of gathering data. Surveys are lists of questions to be answered by research participants, and can be delivered as paper-and-pencil questionnaires, administered electronically, or conducted verbally. Generally, the survey itself can be completed in a short time, and the ease of administering a survey makes it easy to collect data from a large number of people.
14.8K
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:16Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
01:11Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K